20 March 2026 | 12:43AM HKT Equity Research Giant Biogene Holding (2367.HK) 2H25 results sales/NP in line while OP slightly better; Robust outlook; Buy 2367.HK 12m Price Target: HK$46.00 Price: HK$30.86 Upside: 49.1% Giant Biogene 2H25 results were broadly in line with expectations with sales/NI down 20%/32% yoy, 1%/-1% versus GSe, or 4%/6% below VA consensus. Full year 2025 revenue/NI declined by 0.4%/7.2% to Rmb5.52bn/Rmb1.91bn, largely in line with GSe, or 2%/3% below consensus. We note better than expec ...